Ionis Pharmaceuticals, Inc. Proceeds from Issuance of Warrants
Ionis Pharmaceuticals, Inc. (IONS) reported Proceeds from Issuance of Warrants of $0 for the 12-month period ending 2023-12-31, per its 10-K filed 2024-02-21.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOfWarrants · last filed 2024-02-21
- Ionis Pharmaceuticals, Inc. proceeds from issuance of warrants for the quarter ending 2022-12-31 was $0.00.
- Ionis Pharmaceuticals, Inc. proceeds from issuance of warrants for the quarter ending 2022-09-30 was $0.00.
- Ionis Pharmaceuticals, Inc. proceeds from issuance of warrants for the quarter ending 2021-12-31 was $0.00.
- Ionis Pharmaceuticals, Inc. proceeds from issuance of warrants for the quarter ending 2021-09-30 was $0.00.
- Ionis Pharmaceuticals, Inc. proceeds from issuance of warrants for fiscal 2023 was $0.00.
- Ionis Pharmaceuticals, Inc. proceeds from issuance of warrants for fiscal 2022 was $0.00, a 100.00% decline from fiscal 2021.
- Ionis Pharmaceuticals, Inc. proceeds from issuance of warrants for fiscal 2021 was $89.75M.
- Ionis Pharmaceuticals, Inc. proceeds from issuance of warrants for fiscal 2020 was $0.00, a 100.00% decline from fiscal 2019.
| Period end | Proceeds from Issuance of Warrants 1 month | Proceeds from Issuance of Warrants 3 month | Proceeds from Issuance of Warrants 6 month | Proceeds from Issuance of Warrants 9 month | Proceeds from Issuance of Warrants 12 month |
|---|---|---|---|---|---|
| 2023-12-31 | $0.00 10-K · filed 2024-02-21 | ||||
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-21 | $0.00 derived: sum of 2 quarters · filed 2024-02-21 | $0.00 10-K · filed 2024-02-21 | ||
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $0.00 10-Q · filed 2022-11-09 | |||
| 2022-06-30 | $0.00 10-Q · filed 2022-08-09 | ||||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-21 | $0.00 derived: sum of 2 quarters · filed 2024-02-21 | $89.75M 10-K · filed 2024-02-21 | ||
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $89.75M 10-Q · filed 2022-11-09 | |||
| 2021-06-30 | $89.75M 10-Q · filed 2022-08-09 | ||||
| 2021-04-30 | $89.80M 10-Q · filed 2022-11-09 | ||||
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-22 | $0.00 derived: sum of 2 quarters · filed 2023-02-22 | $0.00 10-K · filed 2023-02-22 | ||
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-03 | $0.00 10-Q · filed 2021-11-03 | |||
| 2020-06-30 | $0.00 10-Q · filed 2021-08-04 | ||||
| 2019-12-31 | $56.10M 10-Q · filed 2022-11-09 | $56.11M 10-K · filed 2022-02-25 | |||
| 2018-12-31 | $0.00 10-K · filed 2021-02-24 | ||||
| 2017-12-31 | $0.00 10-K · filed 2020-03-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |